Cemiplimab (Libtayo) — CPB 0942 | AETNA Coverage Update

TL;DR: Aetna, a CVS Health company, modified CPB 0942 governing cemiplimab-rwlc (Libtayo) coverage, effective September 26, 2025. Billing teams need to review medical necessity criteria across six tumor types and confirm prior authorization is in place before claims hit J9119.

This update to the Aetna cemiplimab coverage policy touches every oncology practice billing Libtayo for commercial members. CPB 0942 Aetna now covers cemiplimab-rwlc across a wider set of indications — including cutaneous squamous cell carcinoma, basal cell carcinoma, non-small cell lung cancer, vulvar cancer, and others — each with specific criteria that determine whether J9119 gets paid or denied. If your team isn't building prior authorization requests around the exact criteria in this policy, you're leaving money on the table and setting up claim denials downstream.

Quick-Reference Table

Aetna Cemiplimab Coverage Criteria and Medical Necessity Requirements 2025

Aetna's cemiplimab coverage policy requires precertification for every claim. No exceptions, no retrospective approvals. Call (866) 752-7021 or fax (888) 267-3277 before treatment starts.

The medical necessity bar varies significantly by indication. For CSCC, Aetna covers Libtayo in three scenarios: as neoadjuvant single-agent therapy for very high risk locally advanced or unresectable disease, as adjuvant single-agent therapy after surgery and radiation for high-recurrence-risk disease, and as single-agent treatment for metastatic, locally advanced, or recurrent CSCC when curative surgery or curative radiation isn't an option. That last bucket has a combination-use restriction — cemiplimab must be used as a single agent, not paired with other systemic therapy.

Basal cell carcinoma coverage under this policy adds a sequencing requirement. The member must have already received a hedgehog pathway inhibitor — vismodegib (Erivedge) or sonidegib (Odomzo) — or a hedgehog pathway inhibitor must be clinically inappropriate. Then Aetna requires locally advanced disease, nodal disease where surgery isn't feasible, or metastatic disease. Document the hedgehog pathway inhibitor history explicitly in your prior authorization request. Missing that step is one of the fastest paths to a denial.

For non-small cell lung cancer, Libtayo billing under this policy has the most layered criteria of any indication here. First-line single-agent use requires a PD-L1 Tumor Proportion Score of 50% or higher. First-line combination use with platinum-based chemotherapy doesn't carry that TPS threshold, but the tumor cannot have EGFR exon 19 deletions, L858R mutations, ALK rearrangements, or ROS1 aberrations — unless tissue testing wasn't feasible. The policy also covers maintenance therapy after first-line cemiplimab, either as a single agent or in combination with pemetrexed, with the same biomarker exclusions. Subsequent-line therapy in combination with platinum-based chemotherapy is also covered.

The site-of-care utilization management policy applies to Libtayo infusions. Review Aetna's Site of Care for Specialty Drug Infusions policy before scheduling infusions in a hospital outpatient setting if a lower-cost site is clinically appropriate. Aetna will scrutinize this. A denial based on site of care is a different problem than a denial based on medical necessity — make sure your team knows which fence they're on.

Aetna Cemiplimab Exclusions and Non-Covered Indications

This is the one that will trip up the most claims: Aetna considers a member ineligible for Libtayo if they have experienced disease progression while on any PD-1 or PD-L1 inhibitor therapy.

That includes pembrolizumab (Keytruda, billed as J9271), nivolumab (Opdivo, billed as J9299), cemiplimab itself (J9119), atezolizumab (Tecentriq, J9022), avelumab (Bavencio, J9023), and durvalumab (Imfinzi). If your patient progressed on any of these agents, Aetna will not cover a switch to or continuation of cemiplimab under this coverage policy. Full stop.

The real-world implication: your prior authorization request needs to confirm the absence of checkpoint inhibitor progression. If the patient's chart shows prior PD-1 or PD-L1 therapy, your team needs to document that the prior therapy was completed — not that the patient progressed through it. That distinction drives approval or denial. Pull the oncologist's notes before you submit.

Coverage Indications at a Glance

Aetna Cemiplimab Billing Guidelines and Action Items 2025

1. Audit every active Libtayo prior authorization before September 26, 2025.
Compare your current auth approvals against the updated indication-level criteria in CPB 0942. Any approval that doesn't map cleanly to a covered indication under the revised policy is a claim denial waiting to happen.

2. Build your prior auth requests around Aetna's exact criteria language.
Vague clinical summaries won't cut it here. For NSCLC, document the PD-L1 TPS result, the biomarker test results (EGFR, ALK, ROS1), and the line of therapy explicitly. For BCC, document prior hedgehog pathway inhibitor use or clinical contraindication. Aetna's medical reviewers are reading for specific criteria — write to them, not to a general clinical audience.

3. Document the absence of prior checkpoint inhibitor progression for every patient.
Before you submit a prior auth for J9119, confirm in writing that the patient did not progress on a PD-1 or PD-L1 inhibitor. If prior immunotherapy is in the record, get explicit documentation from the oncologist that the patient completed therapy without progression — not just that they received it. This is the most common reason cemiplimab billing results in denial.

4. Confirm site of care before scheduling infusions.
Aetna's site-of-care utilization management policy applies to Libtayo. If you're scheduling in a hospital outpatient setting, document medical necessity for that site. If a freestanding infusion center is clinically appropriate, that's where Aetna expects the infusion to happen. A site-of-care denial on a $10,000+ infusion hits your reimbursement hard.

5. Use HCPCS code J9119 correctly on every claim.
J9119 is billed per 1 mg of cemiplimab-rwlc administered. The standard dose is 350 mg IV every three weeks, so you're billing 350 units of J9119 per infusion. Errors here don't just cause underpayment — they flag claims for review. Pair J9119 with the appropriate chemotherapy administration code from the 96401–96450 range based on the infusion route and duration.

6. Cross-reference ICD-10-CM codes against the 779 diagnosis codes in the policy.
CPB 0942 lists 779 ICD-10-CM codes. Not every cancer diagnosis maps to a covered indication under this policy. Verify your diagnosis code is on the covered list — especially for less common indications. An ICD-10 code that doesn't match the covered indication for that patient's specific presentation will generate a claim denial.

7. If your patient population includes complex cases with mixed checkpoint inhibitor histories, loop in your compliance officer before the September 26, 2025 effective date. The exclusion criteria for prior PD-1/PD-L1 progression intersect with treatment sequencing in ways that vary by tumor type. Don't guess on those cases.

CPT, HCPCS, and ICD-10 Codes for Cemiplimab Under CPB 0942

HCPCS Codes — Covered When Selection Criteria Are Met

HCPCS Codes — Related to CPB (Comparator/Exclusion Context)

These codes appear in the policy as reference agents — primarily relevant to the prior PD-1/PD-L1 progression exclusion.

CPT Codes — Chemotherapy Administration (96401–96450) and Radiation Oncology (77261–77799)

These codes cover the administration side of cemiplimab billing. Select the correct code based on infusion method, duration, and clinical setting.

The full chemotherapy administration code range listed in CPB 0942 runs from 96401 through 96450. Use the appropriate code for the specific administration method — push vs. infusion, initial vs. concurrent vs. sequential, and add-on codes for extended infusion time. Don't default to 96413 on every claim. Mismatched administration codes draw audits.

Key ICD-10-CM Diagnosis Codes

CPB 0942 lists 779 ICD-10-CM codes. Below is a representative sample of the covered diagnosis codes drawn from the policy data. Verify your specific code against the full list in the policy before billing.

The full ICD-10-CM list in this policy is extensive — 779 codes covering malignancies across multiple tumor sites. Pull the complete list from CPB 0942 on Aetna's site and cross-reference every diagnosis before claim submission.